Spider Veins & Varicose Veins Treatment: Laser Therapy, Sclerotherapy & Thermal Ablation — Cost, Top Hospitals & Success Rates | MyMedicPlus

Chronic venous disease (CVD) of the lower extremities affects an estimated 25–33% of women and 10–20% of men in Western populations, ranging from cosmetically distressing spider veins (telangiectasias) to debilitating varicose veins, skin changes, and venous leg ulcers. The CEAP classification (Clinical-Etiology-Anatomy-Pathophysiology) provides the international standard for grading severity: C0 (no visible disease) through C6 (active venous ulcer), with C1 denoting telangiectasias and reticular veins, C2 varicose veins, C3 oedema, C4a–b skin changes (lipodermatosclerosis, pigmentation), C5 healed ulcer, and C6 active ulcer. The majority of patients presenting for treatment are C1–C2.

The pathophysiological basis of varicose veins is venous reflux — failure of the venous valve mechanism in the great saphenous vein (GSV), small saphenous vein (SSV), or perforator veins — leading to sustained ambulatory venous hypertension. Spider veins (telangiectasias <1mm) and reticular veins (1–3mm) often coexist and may be fed by refluxing tributary veins without overt GSV or SSV incompetence.

Assessment prior to any intervention requires duplex ultrasound mapping — performed by a trained vascular technologist or phlebologist — to identify the site, extent, and direction of reflux; map GSV and SSV diameters; and identify perforator incompetence. A reflux duration >0.5 seconds in superficial veins (>1 second in deep veins) on Valsalva or manual compression-release confirms significant incompetence. Duplex also identifies concomitant deep venous thrombosis (DVT) or post-thrombotic syndrome (PTS), which alter management.

The treatment landscape has undergone a revolution over the past two decades. NICE Technology Appraisal 349 (2013) — updated in the NICE Clinical Guideline CG168 — established that endovenous thermal ablation (EVLA or RFA) is preferred over surgical ligation and stripping as the first-line treatment for GSV and SSV incompetence due to superior clinical outcomes, lower complication rates, faster recovery, and equivalent or better long-term recurrence rates. This guideline change fundamentally shifted varicose vein management away from traditional operating-room surgery toward outpatient, ultrasound-guided, minimally invasive procedures.

Treatment modalities are matched to venous disease category according to CEAP classification and duplex findings:

• C1 — Telangiectasias (spider veins, <1mm) and reticular veins (1–3mm): Treated primarily with liquid sclerotherapy using low-concentration polidocanol (0.25–0.5%) or sodium tetradecyl sulphate (STS 0.1–0.2%), or with transcutaneous laser (Nd:YAG 1064nm). Duplex should first exclude underlying refluxing feeder veins that would cause rapid recurrence if not addressed first.
• C2 — Varicose veins (>3mm, dilated, tortuous superficial veins): The most common presenting complaint. When associated with GSV or SSV reflux confirmed on duplex, the primary treatment is ablation of the truncal incompetent vein (EVLA, RFA, MOCA, or cyanoacrylate), followed by foam sclerotherapy or phlebectomy of the tributary varicosities if they do not resolve spontaneously 6–12 weeks after truncal ablation.
• C3 — Venous oedema: Oedema without skin changes. Management focuses on treating underlying reflux and prescribing graduated compression hosiery (Class 2, 23–32 mmHg or higher). Diuretics are not indicated for pure venous oedema.
• C4a — Skin pigmentation and eczema; C4b — Lipodermatosclerosis and atrophie blanche: Advanced chronic venous insufficiency requiring aggressive duplex-guided intervention — often foam sclerotherapy of feeding veins as well as truncal ablation — plus comprehensive compression therapy and emollient skin care.
• C5/C6 — Healed or active venous leg ulcers: The EVRA trial (2018, NEJM) demonstrated that early endovenous ablation of superficial venous reflux significantly accelerated venous ulcer healing compared to deferred treatment. C6 active ulcers are a medical priority; duplex-guided foam sclerotherapy of perforator veins feeding the ulcer bed alongside multilayer compression bandaging is the cornerstone of care.

Eligibility is assessed through clinical examination, symptom evaluation, and duplex ultrasound:

• Symptom-based eligibility: Patients with symptomatic varicose veins (aching, heaviness, leg fatigue, itching, or swelling worsened by prolonged standing, relieved by elevation) are candidates for treatment. Purely cosmetic C1–C2 disease without symptoms is also eligible for treatment but may not be covered by insurance/NHS in many jurisdictions.
• Duplex prerequisites: NICE CG168 recommends offering treatment to patients with confirmed truncal reflux (GSV, SSV, or accessory saphenous veins) on duplex. Isolated C1 telangiectasias without underlying truncal reflux can proceed directly to sclerotherapy or laser.
• Contraindications to endovenous ablation: Active DVT or acute thrombophlebitis in the target vein; non-ambulatory patient; severe peripheral arterial disease (ABI <0.5 — compression is contraindicated, and thermal ablation carries risk of arterial injury); known hypercoagulable states (AT III deficiency, Factor V Leiden) require specialist haematology review before thermal ablation.
• Contraindications to foam sclerotherapy: Known right-to-left cardiac shunt (patent foramen ovale — PFO) is a relative contraindication to foam sclerotherapy due to theoretical paradoxical embolism risk; bubble-contrast echocardiography pre-treatment is recommended in patients with neurological symptoms or known PFO. History of migraine with aura requires discussion — foam microemboli may trigger migraine in susceptible individuals.
• Pregnancy: Varicose veins frequently appear or worsen in pregnancy. Conservative management (compression hosiery) is first-line during pregnancy; endovenous ablation should be deferred to at least 3 months postpartum to allow spontaneous improvement.
• Anticoagulation: Patients on anticoagulants (warfarin, DOACs) can typically undergo foam sclerotherapy and non-thermal ablation without interruption; thermal ablation under tumescent anaesthesia is also generally safe without anticoagulation interruption unless venous access is complex.

Modern varicose vein treatment offers several well-evidenced outpatient modalities, with choice determined by vein size, anatomy, underlying reflux pattern, and patient preference:

1. Sclerotherapy

• Liquid sclerotherapy: Injection of a liquid sclerosant (polidocanol 0.25–1% or STS 0.1–0.5%) into spider veins and reticular veins under direct vision. The sclerosant damages the endothelium and triggers fibrotic occlusion of the vessel. Multiple sessions are usually required for C1 disease (typically 2–4 sessions, 4–6 weeks apart). This remains the gold standard for spider veins (telangiectasias <1mm).
• Foam sclerotherapy (Tessari technique): Liquid sclerosant is mixed with air or CO² gas in a 1:4 ratio using a two-syringe technique to create a microfoam. Foam displaces blood, maximising contact with the endothelium, allowing lower concentrations to treat larger veins. Evidence from the LAFOS trial (Lattimer et al.) and REACTIV trial confirms foam sclerotherapy has equivalent clinical outcomes to surgery for GSV incompetence at 5 years, with a simpler outpatient profile. Maximum 10 mL foam per session per European Consensus on Foam Sclerotherapy (Breu et al.). For large truncal veins (C2), ultrasound-guided foam sclerotherapy (UGFS) is performed under real-time duplex imaging to ensure accurate foam placement and monitor reflux following injection.

2. Endovenous Laser Ablation (EVLA)

EVLA uses laser energy delivered via a thin fibre introduced into the vein under ultrasound guidance through a small skin puncture. 1470nm wavelength laser (water-absorbed) is the current preferred wavelength — it delivers energy directly to the vein wall with far less intraluminal steam bubble formation than older 810/940nm wavelengths, resulting in less post-procedure bruising and pain while maintaining equivalent occlusion rates (>95% at 1 year). Tumescent anaesthesia (dilute lidocaine in saline) is injected peri-venously before firing — this simultaneously provides anaesthesia and acts as a heat sink protecting the skin.

3. Radiofrequency Ablation (RFA / VNUS ClosureFAST)

RFA uses radiofrequency energy delivered through a segmental catheter (ClosureFAST, Medtronic). The catheter is positioned at the saphenofemoral junction, and 20-second treatment cycles at 120°C are applied in 7 cm segments along the vein under tumescent anaesthesia. Meta-analyses show RFA and EVLA have equivalent long-term occlusion and quality of life outcomes; RFA is associated with marginally less post-procedure pain and bruising in some RCTs.

4. Non-Thermal, Non-Tumescent Ablation (NTNT)

• MOCA (Mechanochemical Ablation — ClariVein): A rotating wire tip within the catheter mechanically disrupts the endothelium while simultaneously infusing liquid sclerosant. No tumescent anaesthesia required — allows treatment of veins close to skin or in areas where tumescent is difficult. MOCA vs RFA RCTs show similar 1-year occlusion rates (~90%).
• Cyanoacrylate closure (VenaSeal, Medtronic): N-butyl cyanoacrylate (tissue glue) is injected segmentally into the vein via catheter — no tumescent anaesthesia, no compression hosiery post-treatment in most protocols. The eSCOPE and CAC (ICE-1) trials demonstrate 95%+ occlusion at 3 years, equivalent to thermal modalities. Higher cost of consumables; rare foreign body reaction to the glue.

5. Transcutaneous Laser for Telangiectasias (Nd:YAG 1064nm)

Laser light at 1064nm is absorbed by oxyhaemoglobin within the vessel, generating heat that coagulates the vessel wall without a needle. Best suited for telangiectasias <0.5mm on the face or fine vessels on the leg not accessible to sclerotherapy needles. Requires multiple sessions; results are comparable to sclerotherapy for the smallest vessels but less effective for larger spider veins where sclerotherapy is preferred.

Minimally invasive endovenous procedures offer significant advantages over traditional surgical ligation and stripping:

• Superior patient experience: Outpatient procedures performed under local/tumescent anaesthesia avoid general anaesthetic risks. Patients typically walk out of the treatment room and return to normal activities within 1–2 days, compared to 2–3 weeks recovery from surgical stripping.
• Equivalent or better long-term efficacy: The CLASS trial (Brown et al., BMJ 2015) comparing EVLA, RFA, foam sclerotherapy, and surgery found equivalent clinical effectiveness at 5 years. NICE TA349 concluded EVLA and RFA are preferred over surgery based on this level of evidence.
• Lower complication rate: Wound haematoma, nerve injury (saphenous nerve — up to 39% with surgical stripping in some series), and surgical site infection are substantially less common with endovenous approaches. Post-procedure bruising and pain with modern 1470nm EVLA and NTNT techniques are minimal.
• Symptom relief: Aching, heaviness, and leg fatigue — the primary symptoms of C2 chronic venous disease — resolve in >80% of patients within 4–6 weeks of successful truncal ablation, with CIVIQ-2 and AVVQ quality-of-life scores showing significant and sustained improvement.
• Venous ulcer healing: EVRA trial data: early ablation reduced median time to venous ulcer healing from 82 days to 56 days and significantly increased proportion of ulcers healed at 24 weeks (56% vs 85% with early intervention).
• Cosmetic improvement: Sclerotherapy of C1 telangiectasias achieves 70–90% clearance per course. Most patients require 2–3 sessions for complete clearance of a defined area, with results lasting 3–5 years before recanalisation or new vessel formation may require retreatment.

While varicose vein treatments are safe outpatient procedures, patients should be aware of the following potential complications:

• Deep vein thrombosis (DVT) and endovenous heat-induced thrombosis (EHIT): DVT occurs in approximately 0.3–1% of thermal ablation procedures. EHIT (thrombus extending into the common femoral or popliteal vein from the treated saphenofemoral junction) is a specific complication of EVLA/RFA, occurring in 0.5–2% of cases. Post-procedure duplex ultrasound at 3–5 days is recommended by most protocols to detect EHIT and guide anticoagulation decisions.
• Skin burns and thermal injury: Inadvertent superficial laser or RF energy delivery can cause skin necrosis — minimised by adequate tumescent anaesthesia depth of at least 1 cm between the vein and skin.
• Post-sclerotherapy hyperpigmentation: Haemosiderin deposition along the sclerosed vein causes brownish skin staining in 10–30% of patients after foam or liquid sclerotherapy. Usually temporary (fades over 6–18 months) but can occasionally be permanent, particularly at higher sclerosant concentrations.
• Telangiectatic matting: Fine clusters of new telangiectasias may form adjacent to treated areas, occurring in 15–24% of patients. Thought to result from angiogenesis stimulated by inflammation and pressure changes. Most cases resolve spontaneously; persistent matting can be treated with additional dilute-concentration sclerotherapy.
• Neurological symptoms post-foam: Transient visual disturbance (phosphene), headache, or paraesthesia are reported in 1–2% of foam sclerotherapy patients — attributed to CO²/air microemboli traversing a patent foramen ovale. These are almost always transient, resolving within minutes. Risk is minimised by using CO² rather than air as the foam gas and limiting foam volume.
• Anaphylaxis to sclerosants: Rare (<0.1%) but documented. All treatment rooms should have adrenaline (epinephrine), antihistamines, and a crash kit available. Patients with known polidocanol allergy should receive STS and vice versa.
• Recurrence: Varicose vein recurrence after any treatment modality is a recognised long-term outcome, occurring in approximately 20–30% at 5 years due to new reflux development at the groin junction, perforator incompetence, or neovascularisation. Minimising recurrence requires adequate treatment of all incompetent segments identified on pre-treatment duplex.

Post-treatment follow-up ensures vein occlusion, detects complications, and manages cosmetic residuals:

• Immediately post-procedure (day of treatment): A 20–30 minute walk is encouraged immediately after all endovenous procedures to reduce DVT risk. Class 2 compression hosiery (18–24 mmHg) is applied before leaving the treatment room. Patients should avoid prolonged standing or sitting for the first 48 hours and avoid air travel for 4 weeks after thermal ablation.
• Compression hosiery protocol: European guidelines recommend Class 2 (23–32 mmHg) compression continuously for 2 weeks post-EVLA/RFA and for 3–7 days post-foam sclerotherapy. VenaSeal cyanoacrylate protocols often omit post-procedure compression as a specific advantage of this technique. Compression reduces DVT risk, improves outcomes of sclerotherapy, and reduces post-procedure pain and bruising.
• Duplex follow-up scan (3–5 days post-thermal ablation): Mandatory after EVLA and RFA to detect EHIT. If EHIT Class 3 or 4 (thrombus extending beyond the sapheno-femoral junction into the femoral vein) is identified, therapeutic anticoagulation is typically initiated for 4–8 weeks.
• Clinical review (6–12 weeks post-treatment): Assessment of symptomatic improvement, residual varicosities (which may now be treated with foam sclerotherapy or ambulatory phlebectomy if they persist after truncal ablation), and cosmetic outcome. Duplex at this visit confirms occlusion and identifies any recanalisation requiring further treatment.
• Sclerotherapy sessions for spider veins: Typically spaced 4–6 weeks apart. A standard course for C1 telangiectasias comprises 2–4 sessions depending on the extent of involvement. Post-injection sun avoidance minimises post-inflammatory hyperpigmentation risk in fair-skinned patients.
• Long-term follow-up: Annual clinical review is recommended for patients with C4–C6 disease to monitor skin changes and ulcer recurrence. Patients are advised to maintain compression hosiery long-term for symptomatic relief and to slow disease progression, particularly those with primary valvular insufficiency or post-thrombotic syndrome.

Treatment costs vary substantially by modality, number of veins, number of sessions, and geography:

• Modality cost hierarchy (per session, approximate USD):

• Liquid sclerotherapy (spider veins): $200–$500 per session (typically 2–4 sessions needed)
• Foam sclerotherapy (UGFS): $400–$1,200 per session
• EVLA (endovenous laser, one limb): $1,500–$3,500
• RFA (radiofrequency, ClosureFAST, one limb): $1,500–$3,500
• MOCA (ClariVein): $1,200–$2,800
• VenaSeal (cyanoacrylate): $2,000–$4,500 (higher consumable costs)
• Nd:YAG laser (telangiectasias, per session): $300–$800

• Geographic variation for complete GSV ablation + sclerotherapy course:

• USA: $3,000–$8,000 per limb (partially covered by insurance if symptomatic C2–C6)
• UK (private): £2,000–£5,000; NHS covers symptomatic C2–C6
• India: $500–$1,500 per limb
• Thailand: $800–$2,500 per limb
• Germany: €1,500–€4,000
• Poland / Hungary: €800–€2,000 (popular dental/vein tourism destinations)

Insurance and NHS coverage typically requires demonstrated symptoms (pain, heaviness, oedema, skin changes) and failure of conservative compression therapy for 3 months. Purely cosmetic C1 spider vein treatment is almost universally self-pay. Medical tourists combining vein treatment with a holiday in India or Southeast Asia can achieve significant cost savings, provided the treating centre has a credentialled phlebologist and duplex ultrasound equipment for both pre-treatment mapping and post-treatment EHIT surveillance.

Not all patients require or choose procedural treatment. The following alternatives exist across the spectrum of venous disease severity:

• Compression hosiery (conservative first-line): Class 1 (14–17 mmHg) to Class 3 (34–46 mmHg) graduated compression stockings provide the most widely available, non-invasive management for C2–C4 chronic venous disease. They reduce ambulatory venous hypertension, improve symptom scores by 50–70% in RCTs, and slow disease progression. Compression is mandatory as adjunct therapy for all C4–C6 disease. Long-term compliance is the principal limitation.
• Venotonics (pharmacological): Micronised purified flavonoid fraction (MPFF/Daflon 500mg) has Level 1A evidence from a Cochrane systematic review for symptom reduction and venous ulcer healing adjunct. Rutosides (oxerutins), calcium dobesilate, and horse chestnut seed extract (aescin) are second-tier options. Not curative but useful for symptom management in patients who defer or are unsuitable for procedural treatment.
• Surgical ligation and stripping: Traditional high ligation of the saphenofemoral junction + GSV stripping under general or spinal anaesthesia. Largely superseded by EVLA/RFA per NICE TA349, due to longer recovery, higher wound complication rates, and greater nerve injury risk. Still performed in some health systems where endovenous technology is unavailable. 5-year recurrence rates are comparable to EVLA in modern RCTs.
• Ambulatory phlebectomy (stab avulsion): Removal of tributary varicose veins through tiny skin punctures under local anaesthesia. Often performed as an adjunct to EVLA/RFA for residual varicosities, or as a standalone procedure for isolated tributary varicosities without truncal reflux. Leaves minimal scarring; results are durable.
• Watchful waiting: Asymptomatic C2 varicose veins in young patients or during pregnancy — monitoring without intervention while using compression hosiery is appropriate. The REACTIV trial showed that conservative management over 2 years led to significant quality-of-life deterioration in untreated patients versus those who received treatment, supporting early intervention for symptomatic disease.